TY  - JOUR
AU  - Herrick, Ariane L.
AU  - Pan, Xiaoyan
AU  - Peytrignet, Sebastien
AU  - Lunt, Mark
AU  - Hesselstrand, Roger
AU  - Mouthon, Luc
AU  - Silman, Alan
AU  - Brown, Edith
AU  - Czirjak, Laszlo
AU  - Distler, Joerg H. W.
AU  - Distler, Oliver
AU  - Fligelstone, Kim
AU  - Gregory, William J.
AU  - Ochiel, Rachel
AU  - Vonk, Madelon
AU  - Ancuta, Codrina
AU  - Ong, Voon H.
AU  - Farge, Dominique
AU  - Hudson, Marie
AU  - Matucci-Cerinic, Marco
AU  - Balbir-Gurman, Alexandra
AU  - Midtvedt, Oyvind
AU  - Jordan, Alison C.
AU  - Jobanputra, Paresh
AU  - Stevens, Wendy
AU  - Moinzadeh, Pia
AU  - Hall, Frances C.
AU  - Agard, Christian
AU  - Anderson, Marina E.
AU  - Diot, Elisabeth
AU  - Madhok, Rajan
AU  - Akil, Mohammed
AU  - Buch, Maya H.
AU  - Chung, Lorinda
AU  - Damjanov, Nemanja
AU  - Gunawardena, Harsha
AU  - Lanyon, Peter
AU  - Ahmad, Yasmeen
AU  - Chakravarty, Kuntal
AU  - Jacobsen, Soren
AU  - MacGregor, Alexander J.
AU  - McHugh, Neil
AU  - Mueller-Ladner, Ulf
AU  - Riemekasten, Gabriela
AU  - Becker, Michael
AU  - Roddy, Janet
AU  - Carreira, Patricia E.
AU  - Fauchais, Anne Laure
AU  - Hachulla, Eric
AU  - Hamilton, Jennifer
AU  - Inanc, Murat
AU  - McLaren, John S.
AU  - van Laar, Jacob M.
AU  - Pathare, Sanjay
AU  - Proudman, Susannah
AU  - Rudin, Anna
AU  - Sahhar, Joanne
AU  - Coppere, Brigitte
AU  - Serratrice, Christine
AU  - Sheeran, Tom
AU  - Veale, Douglas J.
AU  - Grange, Claire
AU  - Trad, Georges-Selim
AU  - Denton, Christopher P.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1599
AB  - Objectives The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches. Methods This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or no immunosuppressant. Patients were assessed three-monthly for up to 24 months. The primary outcome was the change in modified Rodnan skin score (mRSS). Confounding by indication at baseline was accounted for using inverse probability of treatment (IPT) weights. As a secondary outcome, an IPT-weighted Cox model was used to test for differences in survival. Results Of 326 patients recruited from 50 centres, 65 were prescribed methotrexate, 118 MMF, 87 cyclophosphamide and 56 no immunosuppressant. 276 (84.7%) patients completed 12 and 234 (71.7%) 24 months follow-up (or reached last visit date). There were statistically significant reductions in mRSS at 12 months in all groups: -4.0 (-5.2 to -2.7) units for methotrexate, -4.1 (-5.3 to -2.9) for MMF, -3.3 (-4.9 to -1.7) for cyclophosphamide and -2.2 (-4.0 to -0.3) for no immunosuppressant (p value for between-group differences=0.346). There were no statistically significant differences in survival between protocols before (p=0.389) or after weighting (p=0.440), but survival was poorest in the no immunosuppressant group (84.0%) at 24 months. Conclusions These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed.
T2  - Annals of the Rheumatic Diseases
T1  - Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
VL  - 76
IS  - 7
SP  - 1207
EP  - 1218
DO  - 10.1136/annrheumdis-2016-210503
ER  - 

@article{
author = "Herrick, Ariane L. and Pan, Xiaoyan and Peytrignet, Sebastien and Lunt, Mark and Hesselstrand, Roger and Mouthon, Luc and Silman, Alan and Brown, Edith and Czirjak, Laszlo and Distler, Joerg H. W. and Distler, Oliver and Fligelstone, Kim and Gregory, William J. and Ochiel, Rachel and Vonk, Madelon and Ancuta, Codrina and Ong, Voon H. and Farge, Dominique and Hudson, Marie and Matucci-Cerinic, Marco and Balbir-Gurman, Alexandra and Midtvedt, Oyvind and Jordan, Alison C. and Jobanputra, Paresh and Stevens, Wendy and Moinzadeh, Pia and Hall, Frances C. and Agard, Christian and Anderson, Marina E. and Diot, Elisabeth and Madhok, Rajan and Akil, Mohammed and Buch, Maya H. and Chung, Lorinda and Damjanov, Nemanja and Gunawardena, Harsha and Lanyon, Peter and Ahmad, Yasmeen and Chakravarty, Kuntal and Jacobsen, Soren and MacGregor, Alexander J. and McHugh, Neil and Mueller-Ladner, Ulf and Riemekasten, Gabriela and Becker, Michael and Roddy, Janet and Carreira, Patricia E. and Fauchais, Anne Laure and Hachulla, Eric and Hamilton, Jennifer and Inanc, Murat and McLaren, John S. and van Laar, Jacob M. and Pathare, Sanjay and Proudman, Susannah and Rudin, Anna and Sahhar, Joanne and Coppere, Brigitte and Serratrice, Christine and Sheeran, Tom and Veale, Douglas J. and Grange, Claire and Trad, Georges-Selim and Denton, Christopher P.",
year = "2017",
abstract = "Objectives The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches. Methods This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or no immunosuppressant. Patients were assessed three-monthly for up to 24 months. The primary outcome was the change in modified Rodnan skin score (mRSS). Confounding by indication at baseline was accounted for using inverse probability of treatment (IPT) weights. As a secondary outcome, an IPT-weighted Cox model was used to test for differences in survival. Results Of 326 patients recruited from 50 centres, 65 were prescribed methotrexate, 118 MMF, 87 cyclophosphamide and 56 no immunosuppressant. 276 (84.7%) patients completed 12 and 234 (71.7%) 24 months follow-up (or reached last visit date). There were statistically significant reductions in mRSS at 12 months in all groups: -4.0 (-5.2 to -2.7) units for methotrexate, -4.1 (-5.3 to -2.9) for MMF, -3.3 (-4.9 to -1.7) for cyclophosphamide and -2.2 (-4.0 to -0.3) for no immunosuppressant (p value for between-group differences=0.346). There were no statistically significant differences in survival between protocols before (p=0.389) or after weighting (p=0.440), but survival was poorest in the no immunosuppressant group (84.0%) at 24 months. Conclusions These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed.",
journal = "Annals of the Rheumatic Diseases",
title = "Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)",
volume = "76",
number = "7",
pages = "1207-1218",
doi = "10.1136/annrheumdis-2016-210503"
}

Herrick, A. L., Pan, X., Peytrignet, S., Lunt, M., Hesselstrand, R., Mouthon, L., Silman, A., Brown, E., Czirjak, L., Distler, J. H. W., Distler, O., Fligelstone, K., Gregory, W. J., Ochiel, R., Vonk, M., Ancuta, C., Ong, V. H., Farge, D., Hudson, M., Matucci-Cerinic, M., Balbir-Gurman, A., Midtvedt, O., Jordan, A. C., Jobanputra, P., Stevens, W., Moinzadeh, P., Hall, F. C., Agard, C., Anderson, M. E., Diot, E., Madhok, R., Akil, M., Buch, M. H., Chung, L., Damjanov, N., Gunawardena, H., Lanyon, P., Ahmad, Y., Chakravarty, K., Jacobsen, S., MacGregor, A. J., McHugh, N., Mueller-Ladner, U., Riemekasten, G., Becker, M., Roddy, J., Carreira, P. E., Fauchais, A. L., Hachulla, E., Hamilton, J., Inanc, M., McLaren, J. S., van Laar, J. M., Pathare, S., Proudman, S., Rudin, A., Sahhar, J., Coppere, B., Serratrice, C., Sheeran, T., Veale, D. J., Grange, C., Trad, G.,& Denton, C. P.. (2017). Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). in Annals of the Rheumatic Diseases, 76(7), 1207-1218.
https://doi.org/10.1136/annrheumdis-2016-210503

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirjak L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt O, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Mueller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanc M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad G, Denton CP. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). in Annals of the Rheumatic Diseases. 2017;76(7):1207-1218.
doi:10.1136/annrheumdis-2016-210503 .

Herrick, Ariane L., Pan, Xiaoyan, Peytrignet, Sebastien, Lunt, Mark, Hesselstrand, Roger, Mouthon, Luc, Silman, Alan, Brown, Edith, Czirjak, Laszlo, Distler, Joerg H. W., Distler, Oliver, Fligelstone, Kim, Gregory, William J., Ochiel, Rachel, Vonk, Madelon, Ancuta, Codrina, Ong, Voon H., Farge, Dominique, Hudson, Marie, Matucci-Cerinic, Marco, Balbir-Gurman, Alexandra, Midtvedt, Oyvind, Jordan, Alison C., Jobanputra, Paresh, Stevens, Wendy, Moinzadeh, Pia, Hall, Frances C., Agard, Christian, Anderson, Marina E., Diot, Elisabeth, Madhok, Rajan, Akil, Mohammed, Buch, Maya H., Chung, Lorinda, Damjanov, Nemanja, Gunawardena, Harsha, Lanyon, Peter, Ahmad, Yasmeen, Chakravarty, Kuntal, Jacobsen, Soren, MacGregor, Alexander J., McHugh, Neil, Mueller-Ladner, Ulf, Riemekasten, Gabriela, Becker, Michael, Roddy, Janet, Carreira, Patricia E., Fauchais, Anne Laure, Hachulla, Eric, Hamilton, Jennifer, Inanc, Murat, McLaren, John S., van Laar, Jacob M., Pathare, Sanjay, Proudman, Susannah, Rudin, Anna, Sahhar, Joanne, Coppere, Brigitte, Serratrice, Christine, Sheeran, Tom, Veale, Douglas J., Grange, Claire, Trad, Georges-Selim, Denton, Christopher P., "Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)" in Annals of the Rheumatic Diseases, 76, no. 7 (2017):1207-1218,
https://doi.org/10.1136/annrheumdis-2016-210503 . .

TY  - JOUR
AU  - Gossec, Laure
AU  - Smolen, Josef S.
AU  - Ramiro, Sofia
AU  - Wit, Maarten de
AU  - Cutolo, Maurizio
AU  - Dougados, Maxime
AU  - Emery, Paul
AU  - Landewe, Robert
AU  - Oliver, Susan
AU  - Aletaha, Daniel
AU  - Betteridge, Neil
AU  - Braun, Juergen
AU  - Burmester, Gerd R. 
AU  - Canete, Juan D. 
AU  - Damjanov, Nemanja
AU  - FitzGerald, Oliver
AU  - Haglund, Emma
AU  - Helliwell, P.
AU  - Kvien, T. K.
AU  - Lories, Rik
AU  - Luger, Thomas
AU  - Maccarone, Mara
AU  - Marzo-Ortega, Helena
AU  - McGonagle, Dennis
AU  - McInnes, Iain B.
AU  - Olivieri, Ignazio
AU  - Pavelka, Karel
AU  - Schett, Georg
AU  - Sieper, Joachim
AU  - van den Bosch, F.
AU  - Veale, Douglas J.
AU  - Wollenhaupt, Juergen 
AU  - Zink, Angela
AU  - van der Heijde, D.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/955
AB  - Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
T2  - Annals of the Rheumatic Diseases
T1  - European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
VL  - 75
IS  - 3
SP  - 499
EP  - 510
DO  - 10.1136/annrheumdis-2015-208337
ER  - 

@article{
author = "Gossec, Laure and Smolen, Josef S. and Ramiro, Sofia and Wit, Maarten de and Cutolo, Maurizio and Dougados, Maxime and Emery, Paul and Landewe, Robert and Oliver, Susan and Aletaha, Daniel and Betteridge, Neil and Braun, Juergen and Burmester, Gerd R.  and Canete, Juan D.  and Damjanov, Nemanja and FitzGerald, Oliver and Haglund, Emma and Helliwell, P. and Kvien, T. K. and Lories, Rik and Luger, Thomas and Maccarone, Mara and Marzo-Ortega, Helena and McGonagle, Dennis and McInnes, Iain B. and Olivieri, Ignazio and Pavelka, Karel and Schett, Georg and Sieper, Joachim and van den Bosch, F. and Veale, Douglas J. and Wollenhaupt, Juergen  and Zink, Angela and van der Heijde, D.",
year = "2016",
abstract = "Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.",
journal = "Annals of the Rheumatic Diseases",
title = "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update",
volume = "75",
number = "3",
pages = "499-510",
doi = "10.1136/annrheumdis-2015-208337"
}

Gossec, L., Smolen, J. S., Ramiro, S., Wit, M. d., Cutolo, M., Dougados, M., Emery, P., Landewe, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G. R., Canete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., Lories, R., Luger, T., Maccarone, M., Marzo-Ortega, H., McGonagle, D., McInnes, I. B., Olivieri, I., Pavelka, K., Schett, G., Sieper, J., van den Bosch, F., Veale, D. J., Wollenhaupt, J., Zink, A.,& van der Heijde, D.. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. in Annals of the Rheumatic Diseases, 75(3), 499-510.
https://doi.org/10.1136/annrheumdis-2015-208337

Gossec L, Smolen JS, Ramiro S, Wit MD, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester GR, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. in Annals of the Rheumatic Diseases. 2016;75(3):499-510.
doi:10.1136/annrheumdis-2015-208337 .

Gossec, Laure, Smolen, Josef S., Ramiro, Sofia, Wit, Maarten de, Cutolo, Maurizio, Dougados, Maxime, Emery, Paul, Landewe, Robert, Oliver, Susan, Aletaha, Daniel, Betteridge, Neil, Braun, Juergen, Burmester, Gerd R. , Canete, Juan D. , Damjanov, Nemanja, FitzGerald, Oliver, Haglund, Emma, Helliwell, P., Kvien, T. K., Lories, Rik, Luger, Thomas, Maccarone, Mara, Marzo-Ortega, Helena, McGonagle, Dennis, McInnes, Iain B., Olivieri, Ignazio, Pavelka, Karel, Schett, Georg, Sieper, Joachim, van den Bosch, F., Veale, Douglas J., Wollenhaupt, Juergen , Zink, Angela, van der Heijde, D., "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update" in Annals of the Rheumatic Diseases, 75, no. 3 (2016):499-510,
https://doi.org/10.1136/annrheumdis-2015-208337 . .

TY  - JOUR
AU  - Jablanovic, Dragoslav
AU  - Ciraj-Bjelac, Olivera
AU  - Damjanov, Nemanja
AU  - Seric, Srdjan
AU  - Radak-Perović, Marija
AU  - Aranđić, Danijela
AU  - Maksimović, Ružica
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5543
AB  - The purpose of this paper is to evaluate the image quality and dose to patients in the radiography of sacroiliac joints and to perform a clinical comparative study of digital and conventional screen-film radiography. Routine radiography of sacroiliac joint was performed in 60 patients using digital and screen-film radiography. The visibility of five anatomical regions and the overall image quality were rated by experienced radiologists. Patient dose assessment in terms of entrance surface air kerma (ESAK) was performed. The digital system showed slightly improved visualisation of specific anatomical structures. Overall image quality was significantly better in the digital when compared with the screen-film imaging system. The average ESAK was 2.4 mGy in screen-film and 3.6 mGy in digital radiography. The digital radiography provided equal or better visibility of anatomical details and overall image quality, but on higher dose levels. Therefore, the practice on digital systems must be optimised.
T2  - Radiation Protection Dosimetry
T1  - Screen-film versus digital radiography of sacroiliac joints: evaluation of image quality and dose to patients
VL  - 155
IS  - 1
SP  - 88
EP  - 95
DO  - 10.1093/rpd/ncs315
ER  - 

@article{
author = "Jablanovic, Dragoslav and Ciraj-Bjelac, Olivera and Damjanov, Nemanja and Seric, Srdjan and Radak-Perović, Marija and Aranđić, Danijela and Maksimović, Ružica",
year = "2013",
abstract = "The purpose of this paper is to evaluate the image quality and dose to patients in the radiography of sacroiliac joints and to perform a clinical comparative study of digital and conventional screen-film radiography. Routine radiography of sacroiliac joint was performed in 60 patients using digital and screen-film radiography. The visibility of five anatomical regions and the overall image quality were rated by experienced radiologists. Patient dose assessment in terms of entrance surface air kerma (ESAK) was performed. The digital system showed slightly improved visualisation of specific anatomical structures. Overall image quality was significantly better in the digital when compared with the screen-film imaging system. The average ESAK was 2.4 mGy in screen-film and 3.6 mGy in digital radiography. The digital radiography provided equal or better visibility of anatomical details and overall image quality, but on higher dose levels. Therefore, the practice on digital systems must be optimised.",
journal = "Radiation Protection Dosimetry",
title = "Screen-film versus digital radiography of sacroiliac joints: evaluation of image quality and dose to patients",
volume = "155",
number = "1",
pages = "88-95",
doi = "10.1093/rpd/ncs315"
}

Jablanovic, D., Ciraj-Bjelac, O., Damjanov, N., Seric, S., Radak-Perović, M., Aranđić, D.,& Maksimović, R.. (2013). Screen-film versus digital radiography of sacroiliac joints: evaluation of image quality and dose to patients. in Radiation Protection Dosimetry, 155(1), 88-95.
https://doi.org/10.1093/rpd/ncs315

Jablanovic D, Ciraj-Bjelac O, Damjanov N, Seric S, Radak-Perović M, Aranđić D, Maksimović R. Screen-film versus digital radiography of sacroiliac joints: evaluation of image quality and dose to patients. in Radiation Protection Dosimetry. 2013;155(1):88-95.
doi:10.1093/rpd/ncs315 .

Jablanovic, Dragoslav, Ciraj-Bjelac, Olivera, Damjanov, Nemanja, Seric, Srdjan, Radak-Perović, Marija, Aranđić, Danijela, Maksimović, Ružica, "Screen-film versus digital radiography of sacroiliac joints: evaluation of image quality and dose to patients" in Radiation Protection Dosimetry, 155, no. 1 (2013):88-95,
https://doi.org/10.1093/rpd/ncs315 . .